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Abstract
Background: In the presence of both HIV infection and cervical intraepithelial neoplasia (CIN),
the risk of cancer development despite treatment may be greater. We investigated clinical
predictors of persistent cytological abnormalities in women who had had a large loop excision of
the transformation zone (LLETZ).
Methods: Women with high grade squamous intraepithelial lesions or worse (HSIL), less severe
abnormalities which persisted and any abnormality in women who are HIV-infected, were referred
to the colposcopy clinic. HIV infection was ascertained by self-report. A LLETZ was performed on
all patients with HSIL or higher on Papanicolaou (Pap) smear or colposcopy, LSIL or higher in
patients who are HIV-infected, where the colposcopy is inadequate, and when there was a
discrepancy between colposcopy and cytology by one or more grades. Women with abnormal
follow-up smears were compared to those with normal smears. We examined the association
between abnormal follow-up smears and demographic and clinical predictors using logistic
regression
Results: The median time between LLETZ and first follow-up Pap smear was rather short at 122
days. Persistent cytological abnormalities occurred in 49% of our patients after LLETZ. Predictors
of persistence included the presence of disease at both margins and HIV infection. Among the
latter, disease at the excision margins and CD4+ cell count were important predictors. In these
women, disease at the endocervical margin, both margins, and disease only at the ectocervical
margin were associated with increased odds of persistent abnormalities on follow-up cervical
smear.
Conclusion:  We showed extremely high risk of cytological abnormality at follow-up after
treatment more so in patients with incomplete excision and in the presence of
immunocompromise. It remains uncertain whether recurrent CIN is a surrogate marker for
invasive cervical cancer.
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Background
Cervical cancer is the second leading cancer in women
after breast malignancy in South Africa (SA)[1]. The life-
time risk of developing invasive cervical cancer (ICC) is 1
in 31 for South African women. The crude rates for ICC
were 26.1 per 100 000 in 1999, with a corresponding age-
standardized incidence rate of 28.7 per 100 000 and the
risk increased with age, peaking at 136.4 per 100 000 in
women between the ages of 65 and 69[2]. Worldwide, the
ratio of mortality to incidence is 55% with a worse prog-
nosis in developing countries[1].
Several studies from Sub-Saharan Africa have shown asso-
ciations between HIV infection and cervical cancer [3-5].
Furthermore, in HIV-infected women, premalignant dis-
ease of the cervix is more frequent, of a higher grade, and
progresses more rapidly[6]. The prevalence of abnormal
Pap smears was between 50% and 75% in HIV-positive
women in two studies in Sub-Saharan Africa[7,8] and in
the Gauteng province of SA, where our clinic is situated
cervical cytological abnormalities are found in 13.7% of
all women. This is a surprisingly high prevalence even
allowing for a high HIV infection rate (30.8% in antenatal
attendees in the same community[9]).
The prevention of ICC includes screening for pre-malig-
nant disease, treatment and follow-up of treated patients.
A National Screening Policy, whereby state health will pay
for three cervical smears in a life-time commencing at the
age of thirty, was instituted in SA in 2001[10]. By the year
2006, 5.2% of screened women were being referred for
colposcopy in the Johannesburg Metropolitan area com-
pared to 3.5% in the UK[11,12].
Local excision and ablation of the cervix is the standard
treatment for CIN2-CIN3. Although treatment reduces the
risk of subsequent ICC[13,14], these women remain at a
5-fold increased risk of ICC as compared to the general
population[15]. Follow-up for recurrent CIN is therefore
an important aspect of the prevention of cancer program.
The identification of meaningful risk factors for persist-
ence will not only pinpoint, those who need to be fol-
lowed up more actively after treatment of a premalignant
lesion, but may designate those who may safely be fol-
lowed at less sophisticated facilities, and perhaps at less
frequent intervals. The objective of this study was to doc-
ument rates and predictors of persistence of premalignant
cervical lesions in women who had had a large loop exci-
sion of the transformation zone (LLETZ) at a "see and
treat" colposcopy clinic in Soweto, South Africa.
Methods
We followed up a cohort of women attending the colpos-
copy clinic at Chris Hani Baragwanath Hospital in
Soweto, South Africa. The clinic is a referral site for
women with abnormal cervical smear results who pre-
dominantly live in Soweto but also are referred from the
southern parts of the Province. Cytological cervical smears
are reported according to the 2001 Bethesda System Ter-
minology[16]. These reports include: invasion, high or
low grade squamous intraepithelial lesion (HSIL or LSIL),
atypical glandular cells of undetermined significance
(AGUS), atypical squamous cells suggesting HG (ASC-H)
or atypical cells of undetermined significance (ASCUS).
Initially HIV status was ascertained by self-report. Volun-
tary counseling and testing (VCT) was only started in
November 2006. HIV positive results were confirmed by
clinical notes of women who self-reported being HIV pos-
itive. The status of those patients who said that they were
HIV negative was recorded as such if the test was done
within the last 6 months. However the result was not
always confirmed. Those who said they tested negative
more than 6 months previously was recorded as
unknown.
We offer a "see and treat service" where such patients are
offered immediate diagnosis and treatment with colpos-
copy and LLETZ [17]. A LLETZ is performed on all patients
with HSIL or higher on cervical smear or CIN 2 or higher
on colposcopy, where the colposcopy is inadequate, or
when there is a discrepancy between colposcopy and
cytology by one or more grade. HIV-infected women with
L SIL or more on cervical smear and CIN 1 or higher on
colposcopy are treated due to the higher progression[6]
and recurrence in these women.
Patients were followed up at six-monthly intervals. Those
women who had not returned by 6 months were con-
tacted by mail or telephone; if there was no response, a let-
ter was hand delivered by a research worker to the listed
home address to encourage follow up or to ascertain sur-
vival. The total number of patients that were lost to fol-
low-up was 420(41.3%). The loss to follow-up according
to HIV status was 176(42%) for HIV positive women,
109(26%) for HIV negative women (self-reported) and
135(32%) for the women who did not know their status.
Owing to the study design, we cannot differentiate
between persistence and recurrence of abnormal lesions.
For the purpose of this study, therefore, any abnormal
cytology after LLETZ was defined as being persistent. Eth-
ical approval for this study was obtained from the Human
Research Ethics Committee (medical) of the University of
the Witwatersrand.
Statistical analyses
Women with abnormal follow-up smears were compared
to those with normal smears using t-tests for continuous
variables and Chi-square tests for categorical variables. We
examined the association between abnormal follow-up
smears and demographic and clinical predictors usingBMC Cancer 2008, 8:211 http://www.biomedcentral.com/1471-2407/8/211
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logistic regression. Bivariate association between the out-
come of interest and predictor variables was first per-
formed. Multivariate association was then examined in a
stepwise logistic regression including only those variables
with a bivariate p-value of 0.2 or greater. Two separate
models were investigated. The first included all partici-
pants, and included HIV status as a predictor variable. The
second model restricted the analysis population to
women who were HIV-infected.
Results
Between April 2003 and November 2006, 1186 women
were referred to the colposcopy clinic at Chris Hani Barag-
wanath Hospital (CHB) in Soweto. Of these, 1016 had a
LLETZ performed and 575 (57%) women returned to the
clinic for a follow-up cervical smear and were included in
this analysis (Figure 1). LLETZ treatment was not offered
to 170 women: 116 of whom were not eligible for treat-
ment at the time (pregnancy, normal cervix on colpos-
copy, CIN 1 in immunocompetent women), 38 had
invasive cervical cancer, and 15 required hysterectomy for
other reasons. 290 women had normal follow-up cervical
Study schema Figure 1
Study schema.
1186 Patients referred for colposcopy 
1016 Patients treated with LLETZ
575 Patients with follow up cervical smear 
448 with no follow up data 
420 lost to follow up 
25 died (unknown causes) 
3 relocated 
170 excluded: 
116 not treated 
38 ICC 
15 treated with hysterectomy 
1 prior hysterectomy BMC Cancer 2008, 8:211 http://www.biomedcentral.com/1471-2407/8/211
Page 4 of 8
(page number not for citation purposes)
smears(50.4%) and 285(49.4%) women had persistently
abnormal smears after LLETZ. We included any abnormal
Pap smear after treatment in the group classified as per-
sistence, that is any grade of abnormality and any Pap
smear after treatment.
The median time from the date of LLETZ to second cervi-
cal smear was 122 days (interquartile range (IQR), 71 –
160 days). There was no difference in the average duration
between LLETZ and follow-up smear for those with an
abnormal(136.1 days) and those with a normal follow-up
smear(136.3 days). There were 80 women who had a sec-
ond procedure in the group with persistence (LLETZ, cone
or hysterectomy). Second treatments were postponed in
some women to allow initiation of ARV therapy or in
women who were not medically fit for surgery. We did not
perform colposcopic examinations on the women with
normal follow-up cytology. The cytologic abnormalities
noted on the follow up smears are listed in Table 1.
Four women had Microinvasion on histology after LLETZ,
one fell pregnant, 2 refused hysterectomy, and one had a
hysterectomy 6 months after the LLETZ. There was no dys-
plasia, only features of HPV infection on the histology. All
4 cases were a stage 1a1.
Age, HIV infection, histology of the excised portion and
the presence of disease at an excision margin were notable
differences between those women with persistent cyto-
logic abnormalities and those with normal follow up
smears (Table 2). We examined associations of women
having an abnormal cervical smear at their follow-up visit
with various clinical predictors using logistic regression
(Table 3). Self-reported HIV status and the presence of dis-
ease at both margins were strongly associated with persist-
ent cytologic abnormalities after LLETZ. Restricting the
analysis only to those women who self -reported them-
selves to be HIV-infected, increasing CD4 count (the CD4
count was the count within 6 months of the treatment
date) was found to be associated with lower odds of
abnormal follow-up smear results, but having either the
endocervical or both margins involved was highly associ-
ated with persistent cytologic abnormalities. In addition,
the presence of CIN3 on the excised tissue resulted in a
marked increase in the risk of recurrence compared to
CIN1 (OR = 3.8, CI = 1.1–13.1) (Table 4).
Discussion
We report high rates of persistence of cytological abnor-
malities on a follow-up cervical smear after initial treat-
ment using LLETZ particularly in women self reporting as
being HIV-infected. Cytological abnormalities after LLETZ
were eight times more frequent in women who self
reported as being HIV infected. However, in HIV-infected
women with a CD4 count of ≥ 500 cells/mm3, this risk
was halved when compared to women with a CD4 count
of <200 cells/mm3. Dysplasia at both the endocervical
and ectocervical excision margins markedly increased the
risk of persistence as compared to absent dysplasia at the
margins (OR = 10.7, CI = 3.0–37.4). In univariate analy-
sis, the risk of persistence with disease present at either
excised margin was double that of no disease at the mar-
gin.
The association of HPV and cervical cancer has been estab-
lished[18]. Impaired cell mediated immunity is a risk fac-
tor for HPV infection and CIN[19]. Observational studies
have shown an association between CIN and co-infection
with HPV and HIV [20]. In this study it was not possible
to distinguish between the effect of HIV infection and
changes in immunity as would be expected in women on
ARV therapy.
Of the 266 women who were HIV-infected, 89(33%) of
them were on ARV therapy and the number of women tak-
ing ARV's were significantly higher in the patients with
subsequent persistence. However, duration of and
response to treatment would be required to assess ARV
therapy as an independent variable predicting persistence
and we did not collect this information. Longitudinal
studies of detection of oncogenic HPV types and cytologic
dysplasia among HIV infected women on HAART indicate
that ARV therapy may result in clearance of HPV and
regression of low grade lesions [21-23].
The histological report contributed to the identification of
women at higher risk of persistence. Firstly, univariate
analysis of the entire group suggests that if the excised
biopsy specimen had margins involved, risk of persistence
was significantly higher. In multivariate analysis, this
effect was marked. However, because of the relatively
small numbers of women in the multivariate analysis, the
ability to draw conclusions from this finding is somewhat
limited. Secondly, histological reports of CIN-2 and CIN-
3 increased the risk of persistence compared to CIN-1. In
addition, a surprising finding in this study was that
increasing age appeared to be protective against persist-
ence as the reported risk of cervical malignancy increases
Table 1: Results Of Follow Up Cytologic Smears Following Large 
Loop Excision Of The Transformation Zone (LLETZ), Chris Hani 
Baragwanath Hospital, Soweto 2003 – 2006.
Normal cervical cytology at follow-up 290 (50.4%)
Cytological abnormalities at follow up 285 (49.6%)
ASCUS 18 (6.3%)
L SIL 136 (47,6%)
ASC-H 5 (1.8%)
AGUS 1 (0.4%)
H SIL 123 (43.2%)
Invasion 2 (0.7%)BMC Cancer 2008, 8:211 http://www.biomedcentral.com/1471-2407/8/211
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with age, peaking at 136.4 per 100 000 in women between
the ages of 65 and 69 in South Africa[2].
In this study, we did not see an association between per-
sistent cytologic abnormalities and use of hormonal con-
traception. This was not thoroughly investigated.
Resumption of safe sex practices is associated with regres-
sion in women with established neoplasia[24,25]. Con-
dom usage has previously been shown to be higher in
women who are HIV positive[26]. This could not be
explored in this study, again limited by the ascertainment
of condom use.
Potential sources of bias in this study include its opera-
tional nature. In this setting, not all eligible women were
responsive to visit reminders or other measures to encour-
age follow up.
In most of the women in this report, we relied on self-
report for HIV serostatus. Even though HIV positivity
could be confirmed by clinical notes, women who
reported an HIV negative status could not always be con-
firmed. In South Africa the stigma of being HIV infected
causes many people to deny their HIV infection. It is prob-
able, therefore that misclassification would err in the
direction of women reporting themselves as HIV-negative,
and, if this is so, the associations we have drawn may be
an underestimate. Compliance rates for treatment of SIL
range widely, 30%–73% [27,28], depending on the set-
ting (e.g., in a developing vs. an inner city population).
Furthermore, we did not record the size of the lesion on
colposcopy nor size of the excised lesion. We did not
record the smoking history or a detailed sexual history
and therefore were unable to adjust for them in the regres-
sion models. The numbers of abnormal cervical smears
may have been inflated by including those that do not tra-
Table 2: Characteristics Of Women With Normal Or Abnormal Follow Up Cytologic Smears Following LLETZ, Chris Hani 
Baragwanath Hospital, 2003 – 2006.
Abnormal*
 (n = 285)
Normal*
 (n = 290)
p-value
Age, mean (sd) 35.1 (8.0) 37.5 (8.9) 0.001
Parity, mean (sd) 2.7 (1.02) 2.98 (0.97) 0.004
Contraceptive method, n (%) reporting use
Norethisterone oenanthate 32 (11.2) 43 (14.8) 0.200
Depomedroxyprogesterone acetate 29 (10.2) 48 (16.6) 0.025
Intra-uterine contraceptive device 3 (1.1) 4 (1.4) 0.721
Progestogen-only pill 3 (1.1) 7 (2.4) 0.212
Combined oral contraceptive 20 (7.0) 26 (9.0) 0.389
Sterilization 9 (3.2) 19 (6.6) 0.059
HIV status, n (%) self-reporting status <0.0001
Negative 37 (13.0) 112 (38.6)
Positive 184 (64.6) 82 (28.3)
Unknown 64 (22.5) 96 (33.1)
CD4, n (%) <0.0001
<200 91 (55.5) 23 (31.1)
200 – 499 59 (36.0) 33 (44.6)
>499 14 (8.5) 18 (24.3)
On antiretroviral therapy 68 (23.86) 21 (7.24) <0.0001
Baseline smear result, n (%) 0.947
H SIL 216 (75.8) 196 (67.6)
L SIL 34 (11.9) 33 (11.4)
ASCUS 12 (4.2) 12 (4.1)
Histology of excised transformation zone, n (%) 270 255 0.139
Normal 6 (2.2) 7 (2.8)
CIN I 18 (6.8) 28 (11.3)
CIN II 116 (43.9) 90 (36.3)
CIN III 129 (48.9) 126 (50.8)
Microinvasion 1 (0.4) 4 (1.6)
Presence of dysplasia at the margin of excised transformation zone 253 243 <0.0001
Both 35 (13.8) 14 (5.8)
Ectocervical 84 (33.2) 46 (18.9)
Endocervical 35 (13.8) 35 (14.4)
Margins clear 99 (39.1) 148 (60.9)
* Numbers in each category may not sum to the total for the column owing to missing values.BMC Cancer 2008, 8:211 http://www.biomedcentral.com/1471-2407/8/211
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ditionally require immediate treatment. However, an
audit at our clinic in 2006 showed that patients with cer-
vical smears demonstrating L SIL had CIN2/3 on histolog-
ical examination of excised biopsy specimens in
68.5%[29]. HPV testing is not routinely available in our
clinical setting.
Factors previously shown to predict persistence of prema-
lignant cervical lesions include the presence of disease at
the margins[30], the grade of CIN [30], oncogenic HPV
types[31], HPV variants[30], immunocompetence unre-
lated to HIV factors, age, smoking[32], and sexual behav-
iour[33]. In some studies, clear margins did not guarantee
eradication [34-36]. Lesion size has a variable association
with persistence[37] and the presence of disease at the
excision margins may be related to lesion size or excision
technique but we did not see any difference in rates of per-
sistence between the two operators (data not shown). In
addition, the choice of treatment modality impacts on
rates of persistence. Among HIV-infected women, persist-
ence of SIL after Cryotherapy has been reported to be
between 48% and 100%, and after conization between
18% and 71%[38,39].
More intensive, long-term follow-up of HIV infected
women after LLETZ is warranted and provider-initiated
HIV testing should therefore be offered in any patient with
an abnormal cervical smear result, to enable appropriate
Table 3: Logistic regression using data of all women whose HIV status was known showing associations with persistence of an 
abnormal smears following LLETZ (n = 295).
Univariate 
Odds Ratio 
(95% CI)
Multivariate 
Odds Ratio 
(95%CI)
p-value
HIV infection 6.8 (4.3 – 10.7) 8.2 (4.2–15.8) <0.0001
Disease at excision margin of biopsy specimen
No disease at the excision margins Referent Referent -
Disease at the Ectocervical margin 2.1 (1.4 – 3.2) 2.2 (1.2–4.1) 0.013
Disease at the Endocervical margin 0.96 (0.6 – 1.6) 2.1 (0.9–5.5) 0.09
Both endocervical and ectocervical margins 2.6 (1.4 – 5.0) 10.7 (3.0–37.4) <0.0001
Histology
CIN1 Referent Referent -
CIN2 2.0 (1.0 – 3.9) 2.0 (0.8–5.1) 0.17
CIN3 1.6 (0.8 – 3.0) 2.2 (0.8–6.0) 0.12
Micro-invasion 0.4 (0.04 – 3.8) 2.00 (0.04 – 96.7) 0.73
Age > 35 years (median age) 0.64 (0.5 – 0.9) 0.58 (0.33 – 1.0) 0.06
(n = 295).
Table 4: Logistic regression assessing associations with persistence of abnormal smears following LLETZ: restricted to HIV-infected 
women (n = 196).
Univariate 
Odds Ratio 
(95% CI)
Multivariate 
Odds Ratio 
(95%CI)
p-value
CD4 category (cells/mm3)
<200 Referent Referent -
200–499 0.45 (0.24 – 0.85) 0.4 (0.2–0.8) 0.017
≥500 0.2 (0.085 – 0.45) 0.1 (0.01–0.2) 0.000
Disease at excision margins
Margins not involved Referent Referent -
Ectocervical margin positive 1.7 (0.93 – 3.3) 2.0 (0.9–4.6) 0.089
Endocervical margin positive 2.2 (0.8 – 5.8) 5.6 (1.3–24.8) 0.024
Both endo- and ectocervical margins involved 2.5 (0.86 – 7.1) 4.3 (0.9–19.2) 0.059
Histology of excised transformation zone
CIN1 Referent Referent -
CIN2 2.1 (0.8 – 5.3) 2.5 (0.8–7.8) 0.116
CIN3 2.5 (0.96 – 6.4) 3.8 (1.1–13.1) 0.037BMC Cancer 2008, 8:211 http://www.biomedcentral.com/1471-2407/8/211
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follow up arrangements. Furthermore, our data suggests
that complete excision of the transformation zone should
be the objective of surgical interventions, despite the
potential for an increase in associated procedural compli-
cations. In our setting, it appears reasonable for HIV neg-
ative women who have clear excision margins to have less
intensive follow up, at the level of a community health
centre.
Conclusion
We have observed extremely high rates of persistence of
CIN in HIV-infected women and in women with disease
at the excision margins following LLETZ. More intensive
follow up of women with margins involved by CIN and
especially women who are HIV infected with CD4 count
under 500 is warranted. However, it remains unclear
whether persistent CIN identifies those women at risk for
progression to ICC.
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